Retrospective Analysis of Real-World Treatment Patterns and Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Starting First-Line Systemic Therapy in the United Kingdom
Rattachement africain : gb, de, us, it, ch. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background: The treatment landscape for advanced non-small cell lung cancer (aNSCLC) has evolved rapidly since immuno-oncology (IO) therapies were introduced. This study used recent data to assess real-world treatment patterns and clinical outcomes in aNSCLC in the United Kingdom. Methods: Electronic prescribing records of treatment-naive patients starting first-line (1L) treatment for aNSCLC between June 2016 and March 2018 (follow-up until December 2018) in the United Kingdom were assessed retrospectively. Patient characteristics and treatment patterns were analyzed descriptively. Outcomes assessed included overall survival (OS), time to treatment discontinuation, time to next treatment, and real-world tumor response.Results: In all, 1003 patients were evaluated (median age, 68 years [range, 28-93 years]; 53.9% male). Use of 1L IO monotherapy (0%-25.9%) and targeted therapy (11.8%-15.9%) increased during the study period, but chemotherapy remained the most common 1L treatment at all time points (88.2%-58.2%). Median OS was 9.5 months (95% CI, 8.8-10.7 months) for all patients, 8.1 months (95% CI, 7.4-8.9 months) with chemotherapy, 14.0 months (95% CI, 10.7-20.6 months) with IO monotherapy, and 20.2 months (95% CI, 16.0-30.5 months) with targeted therapy. In the 28.6% of patients who received second-line treatment, IO monotherapy was the most common drug class (used in 51.6%).Conclusions: Although use of 1L IO monotherapy for aNSCLC increased in the United Kingdom during the study period, most patients received 1L chemotherapy. An OS benefit for first-line IO monotherapy vs chemotherapy was observed but was numerically smaller than that reported in clinical trials. Targeted therapy was associated with the longest OS, highlighting the need for improved treatment options for tumors lacking targetable mutations.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Retrospective Analysis of Real-World Treatment Patterns and Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Starting First-Line Systemic Therapy in the United Kingdom
- Date Crossref
- 05/10/2020
- Éditeur
- Springer Science and Business Media LLC
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Swansea Bay University Health Board pays non établi dans la noticeÉtablissement de santé
-
Clatterbridge Cancer Centre NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
-
Nottingham University Hospitals NHS Trust pays non établi dans la noticeÉtablissement de santé
-
Velindre NHS Trust pays non établi dans la noticeÉtablissement de santé
-
South Tees Hospitals NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
-
Bradford Teaching Hospitals NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
-
York Teaching Hospital NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
-
University Hospitals Sussex NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
-
Brighton and Sussex University Hospitals NHS Trust pays non établi dans la noticeÉtablissement de santé
-
Barts Health NHS Trust pays non établi dans la noticeÉtablissement de santé
-
Merck KGaA pays non établi dans la noticeEntreprise
-
Research & Development Institute pays non établi dans la noticeInstitution
Swansea Bay University Health Board, Clatterbridge Cancer Centre NHS Foundation Trust et Nottingham University Hospitals NHS Trust, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.